It appears that your browser may be outdated and performance may be limited. The My Study builder is best viewed with the latest internet browsers. However, if you’d prefer to use our standard form, you can access it below.

Go to Internet Explorer Quick Quote Form

Dismiss this message

Salivary Estradiol

Technical Summary

Analyte Summary
Analyte: Estradiol
Aliases: 17β-estradiol, E2, 1,3,5(10)-estratriene-3,17β-diol
Serum-Saliva Correlation: 0.80
Optimum Collection Volume: 225 μL*
*Add 300 µl to the total volume of all tests for liquid handling
Assay Summary
Methodology: ELISA
Sensitivity: 0.1 pg/mL
Assay Range: 1 pg/mL - 32 pg/mL
Assay Type: Quantitative

Collect Saliva Samples

ESTRADIOL SALIVA COLLECTION CONSIDERATIONS

Better results begin with better saliva collection. This collection protocol features general considerations to maximize salivary ​Estradiol analysis. Use this analyte specific collection protocol to plan your collection methodology and sampling schemes.

APPROVED SALIVARY ESTRADIOL COLLECTION METHODS

Test Saliva Samples

@ Salimetrics
Salimetrics SalivaLab - Easy & Accurate
Order Code (lab): 5160
Transport Requirements: Ship on Dry Ice

Add DNA Analysis to My Study

Considerations for adding Salivary DNA to analyte Studies:

You can combine salivary analytes with easy, accurate, and affordable genomic testing using Salimetrics SalivaLab and the same sample that you are already collecting – no specialized saliva collection devices or additional samples are required.

Don’t know what SNPs are right for you? The SalivaLab’s DNA team specializes in genetic testing services, we recommend you Request a DNA Consult (gratis) to learn more about common considerations such as # of samples, participant ethnicity, and IRB Approval.

All DNA Services

DNA Extraction and Normalization
Single Nucleotide Polymorphism (SNP) Genotyping
VNTR & STR Analysis

References & Salivary Estradiol Research

    1. Abraham, G.E. (1975). The applications of steroid radioimmunoassay to gynecologic endocrinology. In: Taymor, M.L. and Green, T.H. (eds.): Progress in gynecology, Vol. 1, 111-144. New York: Grune and Stratton.
    2. Faiman, C., Winter, S.D., & Reyes, F.I. (1976). Patterns of gonadotropins and gonadal steroids throughout life. Clin Obstet Gynecol, 3(3), 467-483.
    3. Kirschner, M.A., Schneider, G., Ertel, N.H., Worton, E. (1982).  Obesity, androgens, estrogens, and cancer risk.  Cancer Res, 42 (8 suppl), 3281s-3285s.
    4. Labrie, F., Bélanger, A., Cusan, L., Candas, B. (1997).  Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: Intracrinology.  J Clin Endocrinol Metab, 82(8), 2403-9.
    5. Lipson, S.F., & Ellison, P.T. (1996). Comparison of salivary steroid profiles in naturally occurring conception and non-conception cycles. Hum Reprod, 11(10), 2090-96.
    6. Choe, J.K., Khan-Dawood, F.S., Dawood, M.Y. (1982). Progesterone and estradiol in saliva and plasma during the menstrual cycle. Am J Obstet Gynecol, 146, 557-62.
    7. Bao, A.-M., Liu, R.-Y., van Someren, E.J., et al. (2003).  Diurnal rhythm of free estradiol during the menstrual cycle.  Eur J Endocrinol, 148(2), 227-32.
    8. Chang, R.J., Plouffe Jr., L. Schaffer, K.  Physiology of the menopause. In: Comprehensive management of menopause, Lorrain, J., Flouffe Jr., L., Ravnikar, V., Speroff, L., Watts, N., eds.  New York: Springer, 1993.
    9. Reed, M.J., Lai, L.C., Owen, A.M., et al. (1990).  Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.  Cancer Res, 50(1), 193-96.
    10. Shirtcliff, E.A., Dahl, R.E., Pollak, S.D. (2009). Pubertal development: Correspondence between hormonal and physical development.  Child Dev, 80(2), 327-37.

    1. Simpson, E.R. (2000). Role of aromatase in sex steroid action.  J Mol Endocrinol, 25(2), 149-56.
    2. Winters, S.J., Troen, P. (1986).  Testosterone and estradiol are co-secreted episodically by the human testis.  J Clin Invest, 78(4), 870-73.
    3. Nankin, H.R., Pinto, R., Fan, D.-F., Troen, P. (1975).  Daytime titers of testosterone, LH, estrone, estradiol, and testosterone-binding protein: Acute effects of LH and LH-releasing hormone in men.  J Clin Endocrinol Metab, 41(2), 271-81.
    4. Ouyang, P., Michos, E.D., Kara, R.H. (2006). Hormone replacement therapy and the cardiovascular system: Lessons learned and unanswered questions.  J Am College Cardiol, 47(9), 1741-53.
    5. McCarthy, M.M. (2008). Estradiol and the developing brain. Physiol Rev, 88(1), 91-134.
    6. Balthazart, J., Cornil, C.A., Taziaux, M., et al. (2006). Rapid changes in production and behavioral action of estrogens. Neuroscience, 138(3), 783-91.
    7. Karpuzoglu, E., Ahmed, S.A. (2006).  Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: Implications for immunity, autoimmune diseases, and apoptosis.  Nitric Oxide, 15(3), 177-86.
    8. Colditz, G. A. 1998.  Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst, 90(11), 814-23.
    9. Lépine, J., Audet-Walsh, E., Grégoire, J., et al. (2010)  Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways.  J Clin Endocinol Metab, 95(6), 2689-98.
    10. Sasano, H., Harada, N. (1998). Intratumoral aromatase in human breast, endometrial, and ovarian malilgnancies.  Endocr  Rev, 19(5), 593-607.
    11. Vining, R.F., & McGinley, R.A. (1987). The measurement of hormones in saliva: Possibilities and pitfalls. J Steroid Biochem, 27(1-3), 81-94.
    12. Choe, J.K., Khan-Dawood, F.S., & Dawood, M.Y. (1983). Progesterone and estradiol in saliva and plasma during the menstrual cycle. Am J Obstet Gynecol, 147(5), 557-62.
    13. Shirtcliff, E.A., Granger, D.A., Schwartz, E.B., et al. (2000). Assessing estradiol in biobehavioral studies using saliva and blood spots: Simple radioimmunoassay protocols, reliability, and comparative validity. Horm Behav, 38(2), 137-47.
    14. Ellison, P.T., Lipson, S.F. (1999). Salivary estradiol–A viable alternative? Fertil Steril, 72(5), 951-52.)

Contact: Salimetrics (USA)
View All International Distributors

Salimetrics’ COVID-19 Status – 8 April 2020 – No change to Prior Update:

Salimetrics’ Sales and Customer Service, as well as all other non-laboratory personnel, have successfully transitioned to working remote and are fully able to provide support to our customers.

Our Salimetrics Pennsylvania Manufacturing Center remains open for customer orders and shipments. All Salimetrics’ laboratory personnel are following PPE guidelines per CDC Biosafety Level 2 (BSL-2).

The Salimetrics’ SalivaLab, located in California, is open to receive samples. In accordance with State of California Executive Order N-33-20 effective March 19, 2020, our Carlsbad, California facility, including R&D and SalivaLab personnel, will remain open working on research critical to the COVID-19 response; onsite SalivaLab personnel will be able to receive samples, and in some cases, test and send data.  All Salimetrics’ laboratory personnel are following PPE guidelines per CDC Biosafety Level 2 (BSL-2).

WHAT TO DO BEFORE YOU SEND SAMPLES

SEND SAMPLES NOW

X
COVID-19 Notice